These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25502545)

  • 1. Developing Biomarkers for MS.
    Gnanapavan S; Giovannoni G
    Curr Top Behav Neurosci; 2015; 26():179-94. PubMed ID: 25502545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilaments as biomarkers in multiple sclerosis.
    Teunissen CE; Khalil M
    Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilaments as biomarkers in neurological disorders.
    Khalil M; Teunissen CE; Otto M; Piehl F; Sormani MP; Gattringer T; Barro C; Kappos L; Comabella M; Fazekas F; Petzold A; Blennow K; Zetterberg H; Kuhle J
    Nat Rev Neurol; 2018 Oct; 14(10):577-589. PubMed ID: 30171200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in multiple sclerosis.
    Housley WJ; Pitt D; Hafler DA
    Clin Immunol; 2015 Nov; 161(1):51-8. PubMed ID: 26143623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are neurofilaments valuable biomarkers for long-term disease prognostication in MS?
    Khalil M
    Mult Scler; 2018 Sep; 24(10):1270-1271. PubMed ID: 30066596
    [No Abstract]   [Full Text] [Related]  

  • 7. Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring.
    Preziosa P; Rocca MA; Filippi M
    Expert Rev Neurother; 2020 Aug; 20(8):747-769. PubMed ID: 32326770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Science is 1% inspiration and 99% biomarkers.
    Dubuisson N; Puentes F; Giovannoni G; Gnanapavan S
    Mult Scler; 2017 Oct; 23(11):1442-1452. PubMed ID: 28537780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.
    Singh V; Tripathi A; Dutta R
    Proteomics; 2019 Aug; 19(16):e1800335. PubMed ID: 31119864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis.
    Gray E; Rice C; Nightingale H; Ginty M; Hares K; Kemp K; Cohen N; Love S; Scolding N; Wilkins A
    Mult Scler; 2013 Feb; 19(2):153-61. PubMed ID: 22723571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body fluid biomarkers for multiple sclerosis--the long road to clinical application.
    Teunissen CE; Malekzadeh A; Leurs C; Bridel C; Killestein J
    Nat Rev Neurol; 2015 Oct; 11(10):585-96. PubMed ID: 26392381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Will multiple sclerosis (MS) susceptibility genes one day become biomarkers for MS diagnosis?].
    Fontaine B
    Rev Neurol (Paris); 2012 Nov; 168(11):833-5. PubMed ID: 22959703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder.
    Ziemann U; Wahl M; Hattingen E; Tumani H
    Prog Neurobiol; 2011 Dec; 95(4):670-85. PubMed ID: 21524682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.
    Chase Huizar C; Raphael I; Forsthuber TG
    Cell Immunol; 2020 Dec; 358():104219. PubMed ID: 33039896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA in multiple sclerosis: search for novel biomarkers.
    Gandhi R
    Mult Scler; 2015 Aug; 21(9):1095-103. PubMed ID: 25921051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.
    Dagley LF; Emili A; Purcell AW
    Proteomics Clin Appl; 2013 Jan; 7(1-2):91-108. PubMed ID: 23112123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
    Fawaz CN; Makki IS; Kazan JM; Gebara NY; Andary FS; Itani MM; El-Sayyed M; Zeidan A; Quartarone A; Darwish H; Mondello S
    Expert Rev Proteomics; 2015; 12(6):637-50. PubMed ID: 26479122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.